Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407043 · ClinicalTrials.gov registry record · Phase 4
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
A Phase 4 study, sponsored by Ophthalmic Consultants of Long Island.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT00407043 is a Phase 4 study that has completed, run by Ophthalmic Consultants of Long Island. The registered enrollment target is 5 participants.
The verdict
NCT00407043, a Phase 4 study, has completed, sponsored by Ophthalmic Consultants of Long Island.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
Interventions
- DRUG Restasis
- DRUG Lotemax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00407043
The ClinicalTrials.gov registry entry for NCT00407043 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ophthalmic Consultants of Long Island, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Restasis is the first listed.
NCT00407043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00407043 about?
NCT00407043 is a clinical study titled "Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis". To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of...
What is the current status of trial NCT00407043?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2006-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00407043?
The interventions under investigation include: Restasis (DRUG), Lotemax (DRUG).
Who is sponsoring clinical trial NCT00407043?
This trial is sponsored by Ophthalmic Consultants of Long Island, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.